Immunotherapy for Ovarian Cancer

被引：0

作者：

Porter, Rebecca ^{[1
]}

Matulonis, Ursula A. ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Div Gynecol Oncol, 450 Brookline Ave, Boston, MA 02115 USA

来源：

CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2022年 / 20卷 / 04期

关键词：

Checkpoint inhibitors; immunotherapy; newly diagnosed; ovarian cancer; recurrent; TUMOR-INFILTRATING LYMPHOCYTES; REGULATORY T-CELLS; PLATINUM-RESISTANT; OPEN-LABEL; PROGNOSTIC-SIGNIFICANCE; ANTI-PD-1; ANTIBODY; ANTITUMOR IMMUNITY; PHASE-II; MELANOMA; CHEMOTHERAPY;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy, with poor survival rates among patients who have advanced disease despite recent significant advances in therapy, including therapy targeting the homologous recombination pathway. Evidence that cell-mediated antitumor immunity, as well as documented programmed death ligand 1 expression, is correlated with improved survival in EOC garnered early optimism regarding the utility of immune checkpoint blockade (ICB) in ovarian cancer. However, the results of multiple clinical trials investigating ICB have revealed very low levels of activity of single-agent immune checkpoint inhibitors, and the testing of combination therapies has not yet identified any combinations with robust activity in a significant proportion of patients who have EOC. In this review, we summarize the results of the major studies of ICB monotherapy and combinations; review novel combinations under investigation, including ICB with cellular therapies; and discuss potential candidate biomarkers for improving the selection of patients who may respond to ICB.

引用

页码：240 / 253

页数：14

共 132 条

[1] Selective Inhibition of Regulatory T Cells by Targeting the PI3K-Akt Pathway [J].

Abu-Eid, Rasha ;

Samara, Raed N. ;

Ozbun, Laurent ;

Abdalla, Maher Y. ;

Berzofsky, Jay A. ;

Friedman, Kevin M. ;

Mkrtichyan, Mikayel ;

Khleif, Samir N. .

CANCER IMMUNOLOGY RESEARCH, 2014, 2 (11) :1080-1089

[2] Signatures of mutational processes in human cancer [J].

Alexandrov, Ludmil B. ;

Nik-Zainal, Serena ;

Wedge, David C. ;

Aparicio, Samuel A. J. R. ;

Behjati, Sam ;

Biankin, Andrew V. ;

Bignell, Graham R. ;

Bolli, Niccolo ;

Borg, Ake ;

Borresen-Dale, Anne-Lise ;

Boyault, Sandrine ;

Burkhardt, Birgit ;

Butler, Adam P. ;

Caldas, Carlos ;

Davies, Helen R. ;

Desmedt, Christine ;

Eils, Roland ;

Eyfjord, Jorunn Erla ;

Foekens, John A. ;

Greaves, Mel ;

Hosoda, Fumie ;

Hutter, Barbara ;

Ilicic, Tomislav ;

Imbeaud, Sandrine ;

Imielinsk, Marcin ;

Jaeger, Natalie ;

Jones, David T. W. ;

Jones, David ;

Knappskog, Stian ;

Kool, Marcel ;

Lakhani, Sunil R. ;

Lopez-Otin, Carlos ;

Martin, Sancha ;

Munshi, Nikhil C. ;

Nakamura, Hiromi ;

Northcott, Paul A. ;

Pajic, Marina ;

Papaemmanuil, Elli ;

Paradiso, Angelo ;

Pearson, John V. ;

Puente, Xose S. ;

Raine, Keiran ;

Ramakrishna, Manasa ;

Richardson, Andrea L. ;

Richter, Julia ;

Rosenstiel, Philip ;

Schlesner, Matthias ;

Schumacher, Ton N. ;

Span, Paul N. ;

Teague, Jon W. .

NATURE, 2013, 500 (7463) :415-+

[3] An Overview of Vasculogenic Mimicry in Breast Cancer [J].

Andonegui-Elguera, Marco A. ;

Alfaro-Mora, Yair ;

Caceres-Gutierrez, Rodrigo ;

Caro-Sanchez, Claudia Haydee Sarai ;

Herrera, Luis A. ;

Diaz-Chavez, Jose .

FRONTIERS IN ONCOLOGY, 2020, 10

[4] IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade [J].

Ayers, Mark ;

Lunceford, Jared ;

Nebozhyn, Michael ;

Murphy, Erin ;

Loboda, Andrey ;

Kaufman, David R. ;

Albright, Andrew ;

Cheng, Jonathan D. ;

Kang, S. Peter ;

Shankaran, Veena ;

Piha-Paul, Sarina A. ;

Yearley, Jennifer ;

Seiwert, Tanguy Y. ;

Ribas, Antoni ;

McClanahan, Terrill K. .

JOURNAL OF CLINICAL INVESTIGATION, 2017, 127 (08) :2930-2940

[5]

Baeuerle PA, 2009, CURR OPIN MOL THER, V11, P22

[6] Resistance to Checkpoint Inhibition in Cancer Immunotherapy [J].

Barrueto, Luisa ;

Caminero, Francheska ;

Cash, Lindsay ;

Makris, Courtney ;

Lamichhane, Purushottam ;

Deshmukh, Rahul R. .

TRANSLATIONAL ONCOLOGY, 2020, 13 (03)

[7] Integrated genomic analyses of ovarian carcinoma [J].

Bell, D. ;

Berchuck, A. ;

Birrer, M. ;

Chien, J. ;

Cramer, D. W. ;

Dao, F. ;

Dhir, R. ;

DiSaia, P. ;

Gabra, H. ;

Glenn, P. ;

Godwin, A. K. ;

Gross, J. ;

Hartmann, L. ;

Huang, M. ;

Huntsman, D. G. ;

Iacocca, M. ;

Imielinski, M. ;

Kalloger, S. ;

Karlan, B. Y. ;

Levine, D. A. ;

Mills, G. B. ;

Morrison, C. ;

Mutch, D. ;

Olvera, N. ;

Orsulic, S. ;

Park, K. ;

Petrelli, N. ;

Rabeno, B. ;

Rader, J. S. ;

Sikic, B. I. ;

Smith-McCune, K. ;

Sood, A. K. ;

Bowtell, D. ;

Penny, R. ;

Testa, J. R. ;

Chang, K. ;

Dinh, H. H. ;

Drummond, J. A. ;

Fowler, G. ;

Gunaratne, P. ;

Hawes, A. C. ;

Kovar, C. L. ;

Lewis, L. R. ;

Morgan, M. B. ;

Newsham, I. F. ;

Santibanez, J. ;

Reid, J. G. ;

Trevino, L. R. ;

Wu, Y. -Q. ;

Wang, M. .

NATURE, 2011, 474 (7353) :609-615

[8] SJI 2020 special issue: A catalogue of Ovarian Cancer targets for CAR therapy [J].

Benard, Emmanuelle ;

Casey, Nicholas P. ;

Inderberg, Else Marit ;

Walchli, Sebastien .

SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2020, 92 (04)

[9] Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations [J].

Birkbak, Nicolai Juul ;

Kochupurakkal, Bose ;

Izarzugaza, Jose M. G. ;

Eklund, Aron C. ;

Li, Yang ;

Liu, Joyce ;

Szallasi, Zoltan ;

Matulonis, Ursula A. ;

Richardson, Andrea L. ;

Iglehart, J. Dirk ;

Wang, Zhigang C. .

PLOS ONE, 2013, 8 (11)

[10] Wnt/β-catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer [J].

Bodnar, Lubomir ;

Stanczak, Aleksandra ;

Cierniak, Szczepan ;

Smoter, Marta ;

Cichowicz, Marzena ;

Kozlowski, Wojciech ;

Szczylik, Cezary ;

Wieczorek, Maciej ;

Lamparska-Przybysz, Monika .

JOURNAL OF OVARIAN RESEARCH, 2014, 7

← 1 2 3 4 5 6 7 8 9 10 →